Atlas Trials

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Clinical trial NCT00334932 · UNKNOWN

Trial details

NCT number
NCT00334932
Sponsor
Herbert Irving Comprehensive Cancer Center
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma and Plasma Cell Neoplasm
Start date
2006-02-01
Primary completion
2010-01-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.